Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application ...

Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

In a propensity score-matched analysis, adjuvant therapy was significantly associated with a higher risk for all-cause and cancer-specific mortality and disease recurrence compared with neoadjuvant ...

Hello. It's Mark Kris from Memorial Sloan Kettering. Recently, I presented information about the published trials of neoadjuvant nivolumab chemotherapy vs chemotherapy, showing robust, disease-free ...

Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...

In this analysis of colorectal cancer patients from 2 clinical trials, researchers aimed to assess the effect of physical activity on overall survival.

In this study, researchers aimed to determine whether Ki67 and TILs in residual breast tumors were prognostic for survival in patients with triple-negative breast cancer who received neoadjuvant ...